Plasma and CSF p-tau 217 had equivalent diagnostic performance for biomarker-defined AD. 2 key findings →
Participants: 174 Evidence: low
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
Plasma and CSF p-tau 217 had equivalent diagnostic performance for biomarker-defined AD. 2 key findings →
Participants: 174 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma p-tau217 and p-tau217/Aβ1-42 are effective diagnostic tools. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
CAARS has the potential to predict CAA severity; however, its clinical utility should be evaluated in follow-up studies. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
We report for the first time an association between altered BA profile, genetic variants implicated in AD, and cognitive changes in disease using a large multicenter study. 3 key findings →
Participants: 1,464 Evidence: low
Full summary, score breakdown and related studies → Original source
Medicare beneficiaries with ADRD were at a higher risk of PAHs for certain uncontrolled comorbidities and incurred higher Medicare expenditures compared with matched controls without dementia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
A history of previous exposure to surgery under GA might be associated with an increased risk of dementia, particularly in subjects who have undergone repeated exposure to GA. 2 key findings →
Participants: 21,380 Evidence: low
Full summary, score breakdown and related studies → Original source
In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. 4 key findings →
Participants: 400,000 Evidence: low
Full summary, score breakdown and related studies → Original source
In single predictor models, p-tau231 (AUC = 0.87, p = 0.005) and GFAP (AUC = 0.87, p = 0.01) were associated with amyloid positivity, and p-tau231 remained significant in all multi-predictor models (p-values < 0.02). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Carriers had higher plasma p-tau217 levels than non-carriers. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Heritability estimates were 16% for Aβ42/40, 42% for NfL, and 60% for GFAP. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Specific plasma biomarker combinations predicted amyloid burden in the precuneus, tau in the entorhinal cortex, hippocampal atrophy, and memory decline. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia. 5 key findings →
Participants: 48 Evidence: low
Full summary, score breakdown and related studies → Original source
Age acceleration was significantly associated with sex, clinical diagnosis, and levels of eight plasma biomarkers, including P-tau217 levels. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 96 proteins were decreased in MCI-SNAP compared to CN and MCI-AD. 5 key findings →
Participants: 96 Evidence: low
Full summary, score breakdown and related studies → Original source
OptPRS predicted AD dementia and Aβ positivity, independent of apolipoprotein E (APOE). 5 key findings →
Participants: 1,634 Evidence: low
Full summary, score breakdown and related studies → Original source
Reimbursement of amyloid-positron emission tomography (PET) is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
CAA-PRS was significantly associated with pathological CAA (OR = 1.766, p < 0.001), with an AUC of 0.783 overall and 0.766 (OR = 1.780, p = 0.002) in those with high amyloid burden. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Education partially mediated the effect of adolescent cognition on CI in the cognitive assessment aample and AD8 in the questionnaire sample (Ps < 0.001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Clinical trials testing tau-targeting therapies may benefit from using fluid biomarkers to recruit individuals at risk of tau aggregation. 1 key finding →
Participants: 163 Evidence: low
Full summary, score breakdown and related studies → Original source
These results support plasma p-tau 181 for the detection of AD dementia and the use of blood-based biomarkers for optimal disease detection. 2 key findings →
Participants: 235 Evidence: low
Full summary, score breakdown and related studies → Original source
This study supports that PET- and CSF-related A/T/N profiles can be used to predict accurately the stages of AD neuropathology. 2 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. 5 key findings →
Participants: 445 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings indicate that tau pathology may play a critical role in pathological angiogenesis, contributing to cerebrovascular lesions and neurodegeneration in AD. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age is an important determinant of severity of cortical tau uptake in atypical AD, with young participants more likely to show widespread and severe cortical tau uptake. 3 key findings →
Participants: 42 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated